These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Immunosuppression in inflammatory bowel disease: When, how and how long?]. Gross V Dtsch Med Wochenschr; 2012 Sep; 137(37):1803-5. PubMed ID: 22956222 [TBL] [Abstract][Full Text] [Related]
7. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease. Segars LW; Gales BJ Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685 [TBL] [Abstract][Full Text] [Related]
8. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease]. Moum B Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Lazzerini M; Martelossi S; Marchetti F; Scabar A; Bradaschia F; Ronfani L; Ventura A Aliment Pharmacol Ther; 2007 Feb; 25(4):419-27. PubMed ID: 17269997 [TBL] [Abstract][Full Text] [Related]
10. Infliximab in the treatment of steroid-dependent ulcerative colitis. Armuzzi A; De Pascalis B; Lupascu A; Fedeli P; Leo D; Mentella MC; Vincenti F; Melina D; Gasbarrini G; Pola P; Gasbarrini A Eur Rev Med Pharmacol Sci; 2004; 8(5):231-3. PubMed ID: 15638236 [TBL] [Abstract][Full Text] [Related]
11. Conventional medical management of inflammatory bowel disease. Burger D; Travis S Gastroenterology; 2011 May; 140(6):1827-1837.e2. PubMed ID: 21530749 [TBL] [Abstract][Full Text] [Related]
13. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Rutgeerts P; Van Assche G; Vermeire S Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465 [TBL] [Abstract][Full Text] [Related]
14. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. Saibeni S; Virgilio T; D'Incà R; Spina L; Bortoli A; Paccagnella M; Peli M; Sablich R; Meucci G; Colombo E; Benedetti G; Girelli CM; Casella G; Grasso G; de Franchis R; Vecchi M Dig Liver Dis; 2008 Oct; 40(10):814-20. PubMed ID: 18479986 [TBL] [Abstract][Full Text] [Related]
15. Medical management of patients with difficult-to-treat inflammatory bowel disease. van Hogezand RA Neth J Med; 1994 Aug; 45(2):55-9. PubMed ID: 7936006 [TBL] [Abstract][Full Text] [Related]
16. Management of inflammatory bowel disease in adults. Katz JA J Dig Dis; 2007 May; 8(2):65-71. PubMed ID: 17532817 [TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of inflammatory bowel disease. Mascheretti S; Croucher PJ; Schreiber S Best Pract Res Clin Gastroenterol; 2004 Jun; 18(3):597-609. PubMed ID: 15157830 [TBL] [Abstract][Full Text] [Related]
18. A report on efficacy and safety of azathioprine in a group of inflammatory bowel disease patients in northwest Greece. Christodoulou D; Katsanos K; Baltayannis G; Tzabouras N; Tsianos EV Hepatogastroenterology; 2003; 50(52):1021-4. PubMed ID: 12845970 [TBL] [Abstract][Full Text] [Related]
19. Immunosuppression in inflammatory bowel disease: traditional, biological or both? Van Assche G; Vermeire S; Rutgeerts P Curr Opin Gastroenterol; 2009 Jul; 25(4):323-8. PubMed ID: 19417645 [TBL] [Abstract][Full Text] [Related]
20. [Drug safety, acceptance and effectiveness of 5-aminosalicylic acid (mesalazine) in the treatment of ulcerative colitis and Crohn disease]. Bayerdörffer E; Bock H Leber Magen Darm; 1988 Apr; 18(2):104-13. PubMed ID: 3374251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]